The researchers used an Affymetrix genome-wide SNP array rather than whole-genome sequencing. They reported 52 SNPs that differed among the selected Prakriti groups at their stated statistical threshold after permutation testing. Of the 262 participants, 245 passed initial genotyping quality control, and smaller subsets were used after additional ancestry and outlier analyses. The investigators also examined PGM1, a gene involved in carbohydrate metabolism, as a possible correlate of features attributed to Pitta. They concluded that their preliminary findings supplied material for further study—not that a person’s complete Prakriti could be read directly from DNA.

This distinction matters. Prakriti is an Ayurvedic constitutional assessment based on a pattern of anatomical, physiological, psychological, and behavioural features. Genes may contribute to some of these features, but Prakriti is not equivalent to a single genotype, laboratory test, pulse finding, or consumer DNA report. “Ayurgenomics” is the research programme that investigates possible relationships between Ayurvedic phenotypes and modern genomic, epigenomic, transcriptomic, metabolic, and microbiome measurements. Its clinical applications remain investigational.

What Ayurgenomics Has Actually Found

Published studies have reported several associations, but they differ greatly in design, sample size, technology, and strength of evidence. Most examined selected groups of healthy people with strongly expressed constitutional features. They did not establish universal genetic profiles for every Vata, Pitta, or Kapha individual, and they did not validate genotype-based prescriptions for Ayurvedic medicines.

These findings are scientifically interesting because they suggest that carefully defined Ayurvedic phenotypes may sometimes correspond to measurable biological variation. However, association is not identity or destiny. Results obtained in extreme, preselected groups may not generalize to people with mixed Vata-Pitta, Pitta-Kapha, Vata-Kapha, or relatively balanced constitutions. Replication in larger, diverse, independently assessed populations is still necessary.

Herb Metabolism and the CYP450 Question

Cytochrome P450 enzymes participate in the metabolism of many medicines and other substances, and inherited variants in certain CYP genes can affect the handling of specific pharmaceutical drugs. The verified Prakriti study in this area examined selected CYP2C19 variants. It did not show that all Pitta individuals rapidly metabolize herbs or that all Kapha individuals require lower doses.

It is therefore incorrect to claim that CYP3A4 or CYP3A5 variants have been shown to make Pitta individuals require 30–50% more Ashwagandha or Turmeric. Likewise, the cited research does not demonstrate that CYP2C19 determines the safe dose of Pippali, or that CYP1A2 can be used to select doses of Tulsi, Neem, or Brahmi. A botanical preparation contains numerous constituents, and its absorption, transformation, transport, and elimination may involve several enzymes and non-CYP pathways. The plant part, extract method, formulation, food intake, other medicines, liver and kidney function, age, and product quality can all influence exposure.

Even when a pharmacogenetic result is clinically meaningful for a named prescription drug, it cannot be transferred automatically to an Ayurvedic herb that happens to interact with the same enzyme in a laboratory experiment. A clinically useful dosing rule requires validated information connecting a particular variant, a standardized preparation, measured exposure, safety, and patient outcomes. Such genotype-to-dose guidelines have not been established for Ashwagandha, Brahmi, Triphala, Turmeric, or Pippali.

Disease Vulnerability Is Not Yet Predictable from Prakriti Genomics

Ayurveda considers constitution when evaluating susceptibility, strength, prognosis, and treatment, but modern statements such as “Vata equals neurological disease,” “Pitta equals inflammatory disease,” or “Kapha equals diabetes” are oversimplifications when presented as fixed predictions. Classical assessment also considers the current disorder, affected tissues, digestive capacity, suitability, age, environment, season, strength, and numerous other factors.

No verifiable 2019 PLoS One study was found showing that Kapha-dominant people had higher polygenic risk scores for type 2 diabetes or metabolic syndrome while Vata-dominant people had higher scores for osteoporosis and anxiety. That claim should not be used to market Prakriti assessment as a genomic disease-screening test. Existing studies have identified exploratory associations with selected physiological measurements or disease cohorts, but they have not produced validated Prakriti-specific polygenic scores suitable for diagnosis, prevention, or treatment decisions.

Prakriti assessment may still contribute to a practitioner’s broader understanding of a patient, especially within traditional Ayurvedic clinical reasoning. It must not replace established screening for diabetes, cardiovascular disease, osteoporosis, cancer, psychiatric illness, or other conditions. Family history, symptoms, physical examination, validated risk calculators, and appropriate laboratory or imaging investigations remain essential.

The Microbiome Dimension

Prakriti-associated microbiome research is also preliminary. A 2018 study examined 16S rRNA profiles from 50 men and 63 women in a comparatively homogeneous rural population. Firmicutes and Bacteroidetes were the major phyla across all three groups. Overall alpha-diversity patterns were comparable, and beta-diversity analysis did not separate participants into clear Prakriti clusters. The investigators did identify certain less-abundant taxa that were enriched in particular groups, with notable differences between male and female results.

Smaller studies published in 2019 and 2021 likewise reported differences in the relative abundance of selected gut, oral, or skin organisms among Prakriti groups. These investigations are useful for generating hypotheses, but they do not prove that Kapha constitution inherently has low microbial diversity, a high Firmicutes-to-Bacteroidetes ratio, or a microbiome equivalent to metabolic syndrome.

There is consequently no validated rule for choosing probiotics, fermented foods, Triphala, or other interventions from Prakriti microbiome data. Microbiome composition is affected by diet, location, medications, sanitation, age, recent illness, sequencing methods, and many other variables. Commercial stool reports also vary in analytical quality and often lack proven clinical utility for prescribing treatment in otherwise healthy people.

Rasayana Selection: Classical Individualization, Not Genomic Matching

Classical Ayurveda already provides a detailed framework for individualization, but it is broader than genetic testing. Charaka Samhita, Vimana Sthana 8, describes a tenfold examination that considers the patient’s habitat and body, Prakriti and Vikriti, tissue excellence, compactness and build, measurements, suitability or habituation, mental strength, capacity for food and digestion, exercise capacity, and age. The text also warns that the strength and potency of treatment must be chosen after considering the patient and disease; otherwise medicine may cause harm.

This framework does not support selecting Ashwagandha from an FKBP5 result, Brahmi from the BDNF Val66Met variant, Triphala from a presumed Kapha microbiome signature, or Curcumin from inflammatory SNPs. Research on these plants and molecular pathways may offer hypotheses, but no clinical trials have validated those specific gene-herb matching rules. Fixed extract doses such as 600 or 900 mg of Ashwagandha, 300–450 mg of Brahmi, or 5 g of Triphala cannot be prescribed responsibly from genotype or Prakriti alone.

The Ayurvedic Pharmacopoeia of India serves a different purpose. Its monographs establish official standards concerned with the identity, purity, and strength of Ayurvedic drugs and ingredients. Pharmacopoeial quality is important, but the Pharmacopoeia does not certify genotype-specific indications or doses. A correctly identified, uncontaminated herb can still be unsuitable for a particular person, interact with medicines, or be used in an inappropriate preparation or amount.

What Responsible Precision Ayurveda Can Mean Today

A defensible form of precision Ayurveda begins with careful clinical assessment rather than a commercial gene report. It may integrate a qualified Ayurvedic evaluation with conventional diagnosis, medication review, laboratory findings, dietary history, allergies, organ function, pregnancy status, and monitoring of benefits and adverse effects. Genomics may be added when a healthcare professional identifies a medically established reason, such as a pharmacogenetic test linked to a particular prescription drug.

Ayurgenomics can also contribute at the research level by improving phenotype definition. Instead of grouping all patients with a biomedical diagnosis together, researchers may examine whether rigorously assessed constitutional patterns identify subgroups with different biomarkers or responses. For that approach to become clinically useful, assessment methods must be reproducible, studies must be prospectively registered and adequately powered, and results must be independently replicated before treatment recommendations are made.

Future work may eventually identify reliable relationships among Prakriti, genomics, epigenetics, metabolomics, microbiome patterns, drug response, and clinical outcomes. At present, however, the evidence supports continued investigation rather than routine genomic selection of rasayana herbs or constitution-based alteration of doses.

Using Consumer Genetic Data Safely

Direct-to-consumer DNA services commonly test a selected set of variants rather than providing a complete clinical analysis. A negative consumer result cannot rule out all medically important variants, and an apparently actionable result may need confirmation in a clinical laboratory. The National Human Genome Research Institute also notes that some consumer tests promote traits or interventions without a confirmed gene-to-phenotype relationship or demonstrated clinical utility.

Uploading raw DNA data to a third-party interpretation platform does not turn it into a validated Ayurvedic prescribing tool. Reports may differ because platforms use different databases, assumptions, and variant classifications. Privacy and data-sharing policies should also be reviewed before uploading genomic files. Most importantly, a list of CYP, BDNF, COMT, MTHFR, APOE, or HLA variants should not be used independently to start, stop, increase, or reduce an herbal or pharmaceutical treatment.

Actionable tip: Keep a complete list of medicines, Ayurvedic formulations, extracts, teas, and supplements you use, including brand, plant part, dose, and frequency. Share the list with both your Ayurvedic physician and conventional healthcare provider. When a genetic result appears medically important, request interpretation by a clinician or genetic counsellor familiar with the relevant condition or drug. Do not adjust Ashwagandha, Brahmi, Triphala, Turmeric, Pippali, or any prescription medicine solely from an online genotype report.

Ayurgenomics and genomic-guided Ayurveda remain emerging research fields. The associations described here are not established diagnostic tests or clinical dosing protocols. Consult a qualified Ayurvedic physician and an appropriately trained healthcare provider before using medicinal herbs, combining them with prescription drugs, or acting on pharmacogenetic or direct-to-consumer DNA results.

References

1. Nature (nature.com)
2. Link (link.springer.com)
3. Link (link.springer.com)
4. Classification of human population based on HLA gene polymorphism and the concept of Prakriti in Ayurveda (2005), PubMed
5. EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda (2010), PubMed
6. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed Central
7. Frontiersin (frontiersin.org)
8. Understanding the association between the human gut, oral and skin microbiome and the Ayurvedic concept of prakriti (2019), PubMed
9. Exploring the signature gut and oral microbiome in individuals of specific Ayurveda prakriti (2021), PubMed
10. Charaka Samhita — Rogabhishagjitiya Vimana
11. Ayurvedic Pharmacopoeia of India
12. Ayurvedic Pharmacopoeia of India
13. Ayurgenomics-based frameworks in precision and integrative medicine: Translational opportunities (2023), PubMed Central
14. Genome (genome.gov)

The relationship between the gut microbiome and Ayurvedic constitutional types, or Prakriti, is a legitimate but still exploratory field of research. By June 2026, the peer-reviewed human literature consists mainly of observational bacterial-community studies published between 2018 and 2021, together with functional reanalyses and later reviews. These studies describe a widely shared gut microbiome accompanied by some sex- and Prakriti-associated differences in particular bacterial taxa. They do not establish fixed Vata, Pitta, or Kapha microbiome profiles, diagnostic phylum ratios, causal disease pathways, or clinically validated constitution-specific reference ranges.

A 2025 scoping review screened 94 articles and included six original studies, all conducted in India and published between 2018 and 2021. Its literature search extended through December 2021, so it synthesized earlier work rather than reporting a new 2025 sequencing cohort. The most defensible conclusion through 2026 is that Prakriti may be one of several variables associated with microbial variation, while diet, geography, sex, age, medicines, environment, laboratory methods, and current health remain major determinants of the measured microbiome.

Background: Prakriti, Vikriti, Agni, and the Microbiome

Charaka Samhita, Vimana Sthana 8/95, describes bodily constitution in relation to the predominance of doshas during the formation of the individual. Later Ayurvedic interpretation treats Prakriti as the person’s relatively stable constitutional baseline. This differs from Vikriti, the present state of doshic disturbance that is assessed when evaluating symptoms or disease. Consequently, a person’s current digestion, bowel pattern, inflammation, medication exposure, or microbial profile should not automatically be equated with innate Prakriti.

Ayurveda also does not reduce digestive assessment to constitution alone. Charaka Samhita, Vimana Sthana 6/12, classifies the functional state of agni as sama, vishama, tikshna, or manda. In the tenfold examination of the patient, Prakriti is considered alongside Vikriti, tissue quality, structural compactness, bodily measurements, adaptation or suitability, mental strength, capacity for food, capacity for exercise, and age. This broader framework is important because two people assigned the same predominant Prakriti can have different current digestive capacities, diets, symptoms, strengths, and treatment needs.

The modern microbiome provides a possible biological layer within this individualized assessment, but the concepts are not interchangeable. The gut microbiome is a dynamic ecological community affected by food, medicines, infections, location, sanitation, host biology, and many other exposures. Prakriti is a multidimensional Ayurvedic phenotype based on physical, physiological, and psychological characteristics. A microbial association may therefore be relevant without making a bacterium the modern equivalent of a dosha or agni.

What the Published Sequencing Studies Actually Used

The principal Prakriti microbiome studies used 16S rRNA gene amplicon profiling or related bacterial-community analyses. A 16S study sequences selected regions of a bacterial marker gene and groups the resulting reads into taxonomic units. Shotgun metagenomics instead sequences DNA throughout the sample and can provide broader taxonomic coverage and more direct information about microbial genes when sequencing depth, reference databases, and analysis quality are adequate. These techniques are not equivalent.

Several Prakriti publications discuss microbial “functional potential,” but much of that work inferred functions computationally from 16S-derived taxonomic profiles and reference databases. Such imputed functions are hypotheses about genes that may be represented in the community. They are not direct measurements of microbial gene expression, metabolite production, intestinal permeability, bile-acid turnover, inflammatory signaling, or host physiology. Direct functional claims would require appropriately designed shotgun metagenomics, metatranscriptomics, metabolomics, host measurements, and independent replication.

This distinction corrects a central misconception about the state of the field. The published literature through June 2026 does not contain a verified 312-person, multi-omic, shotgun-metagenomic Prakriti trial from a CSIR-CCMB, IIT Bombay, and AIIMS consortium. Nor does it provide validated species-level profiles that can be assigned uniformly to every Vata-, Pitta-, or Kapha-predominant person.

The 2018 Western Indian Rural Cohort

The foundational large study was published in Frontiers in Microbiology in 2018, not in the Journal of Translational Medicine in 2015. Researchers examined healthy adults from the Vadu Health and Demographic Surveillance System in western India. After sequence-quality filtering, the final analysis included 113 participants: 50 men and 63 women with predominant Vata, Pitta, or Kapha phenotypes. The investigators used 16S rRNA gene profiling and analysed men and women separately.

Bacteroidetes and Firmicutes together represented more than 98% of the detected relative abundance in this cohort and followed broadly similar patterns across Prakriti groups. Overall alpha-diversity measures were comparable among Vata, Pitta, and Kapha, and beta-diversity analysis did not produce Prakriti-specific clustering. The principal whole-community result was therefore substantial overlap rather than three sharply separated microbial ecosystems.

The researchers then examined a core microbiome, defined using taxa present in at least half of the samples, and identified narrower differential-abundance signals. Fifteen signature taxonomic groups met the study’s criteria in women, whereas only two met them in men. This sex difference is methodologically important: a microbial feature detected in one sex cannot automatically be generalized to all people of that Prakriti.

Selected findings were assessed by quantitative PCR in a subset of samples. Prevotella was more abundant among Kapha women, groups containing Eubacterium rectale and Roseburia were enriched among Vata women, and Blautia was enriched among Pitta women. These results support the possibility of subtle, population-specific associations, but they do not establish universal biomarkers or clinical cut-offs.

Vata Prakriti: Verified Microbial Signals

In women from the 2018 cohort, Vata-associated signature taxa included Bacteroides vulgatus, Blautia stercoris, Butyrivibrio crossotus, Clostridium indolis, Eubacterium rectale, Oscillibacter valericigenes, and Roseburia hominis. In men, Fusicatenibacter saccharivorans was the single Vata-associated signature species passing the study’s stated threshold. The presence of E. rectale and R. hominis, both commonly discussed as butyrate-producing organisms, directly contradicts a generalized claim that Vata subjects had uniformly reduced butyrate-producing bacteria.

The 2021 study of 272 healthy individuals reported a shared core microbiome while noting preferential representation of Paraprevotella and members of Christensenellaceae among Vata participants. It also listed Mitsuokella, S24-7 and Barnesiellaceae among Vata-enriched groups in its comparison with a reference catalogue. These signals do not reproduce every taxon identified in the 2018 cohort, illustrating how cohort composition, location, classification method, sequence processing, and statistical criteria can influence results.

Neither study demonstrated that Vata has higher overall diversity, lower functional redundancy, greater intestinal permeability, or a microbiome that causes constipation, diarrhoea, anxiety, or insomnia. Associations between particular organisms and diseases in unrelated populations cannot be transferred directly to healthy Prakriti groups. A taxon can contain strain-level diversity, and its biological effect depends on community context, substrate availability, abundance, host response, and microbial gene activity.

Pitta Prakriti: Verified Microbial Signals

Among women in the 2018 cohort, Pitta-associated signature taxa included Blautia luti, Blautia obeum, Blautia torques, Butyricicoccus pullicaecorum, Gemmiger formicilis, Lachnospira eligens, and a taxon assigned to Mahella. The male Pitta signature was Roseburia inulinivorans. Several of these organisms are capable of producing short-chain fatty acids or are associated with carbohydrate fermentation, but the study did not measure faecal or circulating short-chain fatty acids.

After the two dominant phyla were excluded from one secondary diversity analysis, Pitta women displayed lower diversity and richness but higher evenness than Vata and Kapha women. This pattern was not observed in men, and beta-diversity still did not separate participants by Prakriti. It should therefore be presented as a sex-specific secondary finding rather than a general definition of the Pitta microbiome.

A smaller 2019 observational study analysed stool, oral, and skin microbial samples from people of different Prakriti. Its gut analysis included 18 participants and reported differential abundance of several genera, including greater representation of Bacteroides and Parabacteroides among Pitta participants in that sample. The modest cohort size and differing design make it useful as exploratory evidence, not as confirmation of a universal Bacteroides-dominant Pitta enterotype.

The available Prakriti studies did not establish enhanced bile-salt-hydrolase activity, greater protein or fat digestion, enriched lipopolysaccharide synthesis, increased plasma calprotectin, or constitution-linked inflammatory signaling in Pitta. They also did not demonstrate a joint relationship among Pitta, HLA-DQ alleles, IL1B variants, and Bacteroides abundance. Classical descriptions of Pitta-related qualities cannot by themselves supply these unmeasured molecular results.

Kapha Prakriti: Verified Microbial Signals

In the 2018 study, Prevotella copri was the principal Kapha-associated signature species among women. No male Kapha taxon passed the study’s stringent signature criteria. The 2021 cohort reported Butyricicoccus as preferentially represented in Kapha when its core microbiome was compared with a catalogue of organisms described in healthy populations. These observations are more limited than a claim that Kapha possesses a uniform Firmicutes-dominant microbiome.

The published cohorts did not establish an elevated Firmicutes-to-Bacteroidetes ratio as a Kapha marker. In the 2018 data, Firmicutes and Bacteroidetes were dominant throughout the cohort, with broadly overlapping community patterns across constitutions. More generally, the Firmicutes-to-Bacteroidetes ratio has produced inconsistent findings in obesity research and is too coarse to function as a stand-alone measure of metabolic health.

Neither increased caloric extraction nor adipogenesis was measured in the Kapha participants. The studies also did not demonstrate Kapha-specific enrichment of Ruminococcus gnavus, Blautia obeum, Clostridium clusters IV or XIVa, reduced tryptophan metabolism, diminished serotonin precursors, depression, or motivational impairment. A constitutionally associated taxon should not be converted into a clinical or psychological diagnosis.

Comparison Table: Findings Supported by Human Prakriti Studies

The table separates directly reported observations from interpretations that remain unestablished. It should not be used to diagnose Prakriti, dysbiosis, or disease from a stool sample.

Predicted Functional Profiles: What They Mean

A 2019 analysis re-examined the 113-person western Indian dataset using computationally imputed functional profiles. It reported extensive functional redundancy: different taxonomic communities were predicted to carry many of the same common functions. The authors also described group-associated predicted pathways, including carbohydrate and amino-acid metabolism in Vata, functions related to xenobiotic or toxin processing in Pitta, and pathways discussed in relation to lipid metabolism, medicines, or obesity in Kapha.

These labels should be interpreted cautiously. The analysis predicted functions from taxonomic data and reference genomes; it did not sequence every microbial gene, determine whether the genes were active, quantify pathway products, or measure corresponding host outcomes. Terms such as “obesity-related function” identify a database annotation or association, not a finding that healthy Kapha participants were becoming obese because of their microbes.

A 2020 comparison combined the Indian Prakriti dataset with a smaller Korean Sasang dataset. Prevotella-related community patterns were more prominent in the Indian samples and Bacteroides-related patterns in the Korean samples, emphasizing the strong contribution of population and geography. The paper found some similarities in imputed functions between constitutionally compared classes, but these cross-system findings remain exploratory and depend on proposed correspondences between two distinct traditional classification systems.

The 2021 Gut and Oral Microbiome Study

The largest published Prakriti microbiome cohort identified in the current literature examined fecal and buccal bacterial profiles from 272 healthy individuals. Prevotella, Bacteroides, and Dialister were among the major gut genera, while the oral community prominently included Streptococcus, Neisseria, Veillonella, Haemophilus, Porphyromonas, and Prevotella. A core microbiome was shared across participants despite reported Prakriti-associated taxa.

This combination of commonality and narrower differentiation is consistent with the 2018 findings. The data permit the hypothesis that Prakriti phenotyping may stratify some microbial variation within a population, but they do not create three mutually exclusive microbiome types. A person may carry an organism associated with another group, and relative abundance can change with diet, medication, infection, laboratory processing, or time.

Implications for Personalized Ayurvedic Diet Recommendations

Ayurvedic dietetics can remain individualized without assigning unverified microbial mechanisms to its recommendations. Traditional clinical reasoning considers constitution, current doshic state, agni, habitual suitability, bowel function, appetite, strength, age, season, locality, symptoms, and the qualities of food. Prakriti is one component of that assessment rather than a complete prescription.

For example, a practitioner may favour regular, warm, suitably unctuous and well-prepared meals when dryness, irregular appetite, distension, or other Vata-aggravated features are present. A person with strong heat, burning, excessive sharpness, or Pitta aggravation may receive a different selection and preparation of food. Heaviness, lethargy, excess unctuousness, or Kapha aggravation may call for lighter meals and appropriately stimulating activity. These are traditional applications of qualities and present-state assessment, not treatments proven to increase or suppress particular bacterial families.

The same caution applies to ghee, fermented foods, fibre, spices, probiotics, prebiotics, and herbal formulations. Their effects depend on dose, preparation, overall diet, tolerance, health status, medicines, and the existing microbial community. Ghee should not be described as directly delivering butyrate to colonocytes in the same manner as colonic bacterial fermentation, and a pungent spice should not be presented as a validated method for converting a presumed Kapha microbiome into a different constitutional profile.

There is also no verified randomized trial in Gut Microbes involving 120 participants that demonstrated normalization of Kapha Firmicutes/Bacteroidetes ratios or recovery of Lachnospiraceae in Vata through Prakriti-specific diets. Constitution-guided diet trials remain a valid research direction, but they require standardized Prakriti assessment, prospectively registered protocols, adequate sample sizes, defined clinical outcomes, longitudinal sampling, dietary-adherence measurements, and replication.

Methodological Limitations and Open Questions

The current literature has several limitations that affect interpretation. These concern not only sample size but also how constitution is classified, which participants are selected, what sequencing method is used, and whether a statistical association is reproduced in another population.

• Prakriti assessment varies: A 2025 critical review identified 64 distinct Prakriti assessment tools across 94 studies. Only 20 had undergone any form of validation, and none fully satisfied all criteria in the scale-development framework used by the reviewers. Differences in questionnaires, practitioner judgement, scoring, and thresholds can change group assignment.
• Extreme phenotypes are selective: Several microbiome studies enrolled people with a strong predominance of one dosha to maximize contrast. Many people have dual-dosha constitutions, and findings from extreme Vata, Pitta, or Kapha groups may not transfer to mixed constitutions.
• Most designs are cross-sectional: A stool sample and Prakriti classification measured at one period cannot determine causal direction. Longitudinal studies are needed to separate stable host-associated features from temporary dietary, medical, seasonal, or environmental changes.
• Stool is an incomplete sample: Faecal material mainly represents the distal intestinal community and does not fully describe the small intestine, mucus-associated organisms, spatial microbial structure, microbial activity, or host-microbe interactions at the intestinal surface.
• 16S resolution is limited: Marker-gene sequencing can miss taxa detected by sufficiently deep shotgun sequencing and may not reliably distinguish strains. Closely related strains can have different genes and biological effects.
• Functional prediction is indirect: Functions imputed from 16S profiles are not substitutes for shotgun metagenomics, metatranscriptomics, proteomics, metabolomics, or measured host responses.
• Sex-specific findings require replication: The 2018 study found substantially more signature taxa in women than in men. A constitution-wide statement should not be derived from a signal confined to one sex in one cohort.
• Diet and geography remain major confounders: Regional cuisine, fibre intake, animal-food consumption, sanitation, medications, occupation, socioeconomic conditions, and laboratory procedures can influence microbiome composition independently of Prakriti.
• Relative abundance is compositional: An apparent increase in one organism may reflect a decrease in another rather than a rise in absolute cell number. Quantitative methods are needed when absolute microbial load matters.
• Clinical thresholds are absent: The studies did not define sensitivity, specificity, reference intervals, treatment targets, or validated microbial criteria for diagnosing Prakriti, Vikriti, weak agni, or a doshic disorder.

Replication is especially important because microbiome studies test many organisms and pathways simultaneously. A statistically significant organism in one analysis may not recur under another sequencing region, database, sampling method, diet, population, or statistical model. Future reports should preregister primary outcomes, disclose all tested comparisons, control false-discovery rates, publish analysis code, and validate findings in an independent cohort.

Season, Diet, and the Microbiome

Season is an established consideration in Ayurvedic regimen and clinical evaluation, but the existing Prakriti cohorts do not define a universal “Kapha-season microbiome.” They do not demonstrate that the Firmicutes-to-Bacteroidetes ratio peaks during late winter in accordance with doshic accumulation or aggravation. Seasonal changes in food, temperature, activity, infections, travel, and environment can alter microbial communities, yet those changes must be measured rather than inferred from an Ayurvedic seasonal label.

A rigorous seasonal study would repeatedly sample the same participants, record diet and medication exposure, account for climate and geography, use standardized laboratory methods, and analyse Prakriti and current Vikriti separately. Such a design could examine whether constitution modifies seasonal microbial responses without assuming in advance that a phylum ratio represents Kapha.

Where This Research Is Heading

The most useful next step is not the creation of immediate dosha-specific commercial reference ranges. It is the construction of carefully phenotyped longitudinal cohorts that combine validated Prakriti assessment with diet records, clinical measures, medicines, host genetics, shotgun metagenomics, microbial gene expression, metabolomics, and replication across regions. Such work could determine whether Prakriti adds predictive value after conventional variables are considered.

Intervention studies should also distinguish Ayurvedic personalization from generic healthy-diet effects. A credible trial might compare a standardized constitution-and-Vikriti-guided programme with a nutritionally matched control, measure adherence, prespecify clinical outcomes, and evaluate whether any microbial changes mediate those outcomes. Microbiome changes alone should not be treated as clinical benefit unless linked to validated health measures.

Consumer microbiome testing requires similar restraint. A 2025 international consensus statement concluded that microbiome testing needs standardized methods and validated clinical interpretation before routine use for diagnosis or treatment selection. Current stool reports can describe detected organisms and relative abundances, but they cannot reliably identify a person’s Prakriti, determine which dosha is disturbed, or prescribe an Ayurvedic diet without a full clinical assessment.

The intersection of Ayurveda and microbiome science remains worthwhile because both fields engage with individual variation, diet, environment, and changing physiological states. Its value will depend on preserving the distinctions among classical concepts, measured microbial features, computational predictions, and clinical outcomes. The existing data support further investigation of modest Prakriti-associated microbial differences; they do not yet support a fixed microbial identity for Vata, Pitta, or Kapha.

Selected Peer-Reviewed References

The following publications provide the principal human data, methodological context, and current assessment of the field.

• Chauhan NS, et al. Western Indian Rural Gut Microbial Diversity in Extreme Prakriti Endo-Phenotypes Reveals Signature Microbes. Frontiers in Microbiology. 2018;9:118.
• Mobeen F, et al. Functional signature analysis of extreme Prakriti endo-phenotypes in gut microbiome of western Indian rural population. Bioinformation. 2019;15:490-497.
• Chaudhari D, et al. Understanding the association between the human gut, oral and skin microbiome and the Ayurvedic concept of Prakriti. Journal of Biosciences. 2019;44:112.
• Mobeen F, et al. Comparative gut microbiome analysis of the Prakriti and Sasang systems reveals functional level similarities in constitutionally similar classes. 3 Biotech. 2020;10:379.
• Shalini TV, et al. Exploring the signature gut and oral microbiome in individuals of specific Ayurveda Prakriti. Journal of Biosciences. 2021;46:54.
• Yadav S, Yadav CR, Deepshikha P. A scoping review of scholarly publications on association of Prakriti and gut microbiome. Journal of Research in Ayurvedic Sciences. 2025;9:144-151.
• Venkatesh A, et al. Prakriti (constitutional typology) in Ayurveda: a critical review of Prakriti assessment tools and their scientific validity. Frontiers in Medicine. 2025;12:1656249.

Disclaimer: This article is educational and does not constitute medical advice. Microbiome testing, persistent digestive symptoms, major dietary changes, probiotics, herbs, and individualized Ayurvedic treatment should be discussed with a qualified Ayurvedic practitioner and an appropriate healthcare professional. Stool testing should not replace medical evaluation for pain, bleeding, fever, weight loss, persistent diarrhoea, severe constipation, anaemia, or other concerning symptoms.

References

1. Charaka Samhita — Deha prakriti
2. Frontiersin (frontiersin.org)
3. Astanga Hridaya (siva.sh)
4. LWW Journals
5. Nature (nature.com)
6. Frontiersin (frontiersin.org)
7. Functional signature analysis of extreme Prakriti endophenotypes in gut microbiome of western Indian rural population (2019), PubMed Central
8. Comparative gut microbiome analysis of the Prakriti and Sasang systems reveals functional level similarities in constitutionally similar classes (2020), PubMed Central
9. Ias (ias.ac.in)
10. Exploring the signature gut and oral microbiome in individuals of specific Ayurveda prakriti (2021), PubMed
11. Researcher (researcher.manipal.edu)
12. International consensus statement on microbiome testing in clinical practice (2025), PubMed

That question is scientifically legitimate, but the clinical claims often made from it are much stronger than the evidence. The studies reviewed here do not show that a Pitta-predominant patient needs a higher antihypertensive dose, that a Kapha-predominant patient clears medicines slowly, or that Vata, Pitta, and Kapha can substitute for a pharmacogenetic test. The available literature consists mainly of cross-sectional studies of healthy volunteers, molecular association studies, and reviews.

Peer-reviewed work has appeared in the Journal of Translational Medicine, Proceedings of the National Academy of Sciences, Scientific Reports, Evidence-Based Complementary and Alternative Medicine, and the Journal of Ayurveda and Integrative Medicine. An ACS Chemical Biology article discussed Ayurgenomics as a framework for stratified medicine, but it was not a clinical dosing trial.

Disclosure: Ayurgenomics remains an exploratory research field. Do not change the dose, timing, or choice of any prescribed medicine on the basis of Prakriti. Medication decisions should be made with a qualified physician; Ayurvedic treatment should be supervised by a properly qualified Ayurvedic practitioner, especially when herbs and prescription medicines are combined.

The Ayurgenomics Framework: What Researchers Are Actually Studying

In classical Ayurveda, Prakriti is the relatively stable constitution established from the beginning of life, while a person’s current doshic disturbance is assessed separately. Charaka Samhita, Vimana Sthana 8/95 describes factors associated with the formation of constitution, and 8/96–99 describes characteristics of Kapha-, Pitta-, and Vata-predominant constitutions. Modern Ayurgenomics does not directly prove doshas as molecular entities; it tests whether people classified by an Ayurvedic phenotype show reproducible differences in measurable biological variables.

The most defensible hypothesis is therefore limited: a carefully assessed phenotype may enrich a study group for certain genetic, transcriptomic, biochemical, epigenetic, or metabolic features. Demonstrating such enrichment would not by itself prove that Prakriti predicts response to a medicine. That requires prospective pharmacokinetic or clinical-outcome studies in which drug exposure, therapeutic response, and adverse events are measured directly.

A foundational 2008 study led by Bhavana Prasher and Mitali Mukerji screened 850 volunteers and ultimately included 96 unrelated, ethnically matched healthy participants with predominant Vata, Pitta, or Kapha phenotypes. Contrary to a frequently repeated description, the final sample was not 262 men: it included 48 men and 48 women. The investigators reported group differences in selected biochemical and hematological measures and in gene-expression categories related to processes such as transport, immune response, cyclin-dependent kinase regulation, and blood coagulation. The work was exploratory, used extreme constitutional types, and did not test any drug.

Genome-Wide Variation: What the 2015 Study Found

The 2015 Scientific Reports study is also often misquoted. Researchers assessed 3,416 healthy men aged 20–30, but genome-wide SNP analysis was performed on 262 men with strongly predominant and concordantly classified Prakriti: 94 Vata, 75 Pitta, and 93 Kapha. After permutation testing, 52 SNPs differed among the groups at the study’s stated significance threshold, and principal-component analysis separated the selected study participants.

The authors also applied a statistical model to 297 Indian population samples of known ancestry. Only 37 of those samples satisfied the model’s criteria and were projected into the proposed Prakriti clusters. This was a limited secondary analysis, not independent clinical validation of a Prakriti diagnostic test. The paper further reported Pitta-associated markers in and around PGM1, a gene involved in carbohydrate metabolism.

Importantly, the study did not report that Pitta was enriched for CYP3A4 or CYP2C9 variants, that Kapha was defined by slow drug clearance, or that Vata carried catecholamine-pathway variants that predict psychoactive-drug sensitivity. Those specific statements are not supported by the paper and should not be used in patient counseling.

CYP2C19 and Prakriti: The Main Direct Pharmacogenomic Association

The clearest published Prakriti–drug-metabolism association comes from a study of CYP2C19, published online in 2009 and in its final journal volume in 2011. Investigators screened 489 healthy volunteers and recruited 132 unrelated participants with predominant Prakriti: 63 Kapha, 43 Pitta, and 26 Vata. The sample included both men and women.

Using the alleles tested in that study, the authors classified 91% of the Pitta group as “extensive metabolizers,” while the genotype category labeled “poor metabolizer” occurred in 31% of Kapha, 12% of Vata, and 9% of Pitta participants. The CYP2C19*2/*3 genotype was reported only in Kapha and was associated with Kapha in the study, with a reported odds ratio of 3.5 and a p value of .008.

This result is noteworthy, but its boundaries matter. The researchers studied genotype distribution; they did not administer a CYP2C19 substrate, measure plasma drug concentrations, compare therapeutic outcomes, or establish safe doses for any Prakriti. Allele coverage and metabolizer terminology have also evolved since the study. It is therefore evidence for a possible association requiring replication, not evidence that all Kapha individuals are slow metabolizers or that Prakriti can replace clinical CYP2C19 genotyping.

A Corrected Evidence Map

The strongest verified studies support molecular correlation, not Prakriti-based prescribing. The following table separates what each study observed from the clinical conclusions it cannot establish.

None of these studies was a randomized medication trial, and none produced a clinically validated dosing algorithm. A molecular difference can be real yet still be too small, too population-specific, or too poorly replicated to guide treatment for an individual.

What the Research Demonstrates—and What It Does Not

The evidence supports a modest conclusion: strongly selected Prakriti groups have shown differences in some molecular and biochemical measurements. It does not yet show that a patient’s Prakriti reliably predicts the concentration, benefit, or toxicity of a prescribed drug. Several methodological issues explain why the gap remains large.

Study Populations and Replication

Samples have generally been small after strict phenotypic selection, and some influential studies included only young Indian men or focused on particular Indian ancestry groups. The 2008 study included women, but sex-specific expression differences and greater within-group variability were also observed. Robust clinical use would require independent replication across sexes, ages, regions, ancestries, disease states, and treatment settings.

Assessment Reliability

Prakriti classification is not yet measured by one universally accepted research instrument. A 2025 critical review identified 64 distinct assessment tools used from 1987 through 2024; only 20 had undergone any validation or reliability testing, and only two met seven of the nine criteria used by the reviewers. When studies use different questionnaires, scoring rules, software, or physician judgments, apparently similar labels may not define equivalent groups.

Prakriti, Vikriti, and Confounding

Classical Prakriti should not be described as something that changes with each season, diet, or current illness. Those factors may alter present symptoms, doshic imbalance, laboratory values, gene expression, or how constitution is perceived during assessment. Research must therefore distinguish stable constitutional classification from current vikriti and control for ancestry, body composition, diet, sleep, medications, geography, socioeconomic conditions, and other environmental influences.

Association Is Not Prediction

A statistically different allele frequency between groups does not mean that every person in a group carries the allele, and it does not show that the allele changes a clinical outcome. A useful predictor must add reproducible information beyond established factors, be tested in an external population, and improve a decision such as drug choice, starting dose, monitoring, or avoidance. Existing Ayurgenomics studies have not yet crossed that threshold.

Metabolomics and Other Molecular Correlates

A study published online in 2017 and in print in 2018 in the Journal of Ayurveda and Integrative Medicine examined fasting plasma from 38 healthy men and reported differences in inferred metabolic pathways among Prakriti groups, including branched-chain amino-acid and glycerolipid processes in Pitta and catecholamine, arachidonic-acid, and hydrogen-peroxide processes in Vata.

That small untargeted metabolomics study did not establish that Kapha patients respond differently to NSAIDs or corticosteroids, that Pitta patients clear protein-bound medicines faster, or that any group has a predictable inflammatory baseline. Such clinical inferences would require targeted assays, replication, drug-exposure measurements, and patient outcomes.

A separate PNAS study linked EGLN1 variation, constitution-based stratification, and high-altitude adaptation. This supports the broader idea that detailed phenotyping can help reveal biological associations. It does not validate a universal relationship between dosha and drug metabolism.

Established Pharmacogenomics Must Remain Separate

Conventional pharmacogenomics already contains well-studied gene–drug pairs, but these should not be retrofitted onto Prakriti without direct evidence. Clinical Pharmacogenetics Implementation Consortium guidelines explain how available genotype results may be used for particular medicines; they do not endorse Vata, Pitta, or Kapha as surrogate genotypes.

Warfarin

Warfarin dose requirements can be influenced by variants in CYP2C9, VKORC1, and CYP4F2, together with clinical factors. Current CPIC guidance addresses those measured genotypes. No verified study reviewed here shows that Kapha is enriched for reduced-function CYP2C9 variants or that Prakriti predicts bleeding on warfarin. Anticoagulant dosing must never be altered from constitutional appearance.

Codeine

CYP2D6 genotype can affect conversion of codeine to morphine, and CPIC provides recommendations for known CYP2D6 phenotypes. The Ayurgenomics studies reviewed here do not establish a distribution of CYP2D6 phenotypes by Prakriti. A proposed Vata sensitivity to codeine or psychoactive medicines is therefore unverified.

Statins

The current CPIC statin guideline focuses on SLCO1B1, ABCG2, and CYP2C9 in relation to statin exposure and musculoskeletal symptoms. It does not describe Pitta as a rapid CYP3A4 phenotype or Kapha as a slow-clearance phenotype. Body build or a dosha label cannot be used to estimate statin myopathy risk.

Clinical Implications: What Practitioners Can and Cannot Do Today

Clinicians should not use Prakriti to determine prescription-drug doses. It may remain part of a traditional Ayurvedic assessment, but it is not a validated substitute for medication history, renal and hepatic assessment, therapeutic drug monitoring, evidence-based pharmacogenetic testing, or disease-specific prescribing guidance.

1. Do not infer metabolizer status from dosha. A Pitta label does not prove rapid clearance, and a Kapha label does not prove poor metabolism or accumulation.
2. Use validated gene–drug guidance when relevant. Where a recognized guideline exists, decisions should be based on the actual genotype or phenotype and the patient’s clinical circumstances.
3. Review herb–drug combinations individually. Interaction risk depends on the herb, preparation, dose, product quality, medicine, and patient—not on an unvalidated constitutional shortcut.
4. Keep Ayurvedic reasoning within its evidence and scope. A qualified practitioner may consider Prakriti alongside agni, current doshic imbalance, strength, age, season, diet, and disease, but this does not authorize changing a pharmaceutical dose.

Anyone taking anticoagulants, antiplatelet medicines, immunosuppressants, anticonvulsants, psychiatric medicines, chemotherapy, or other narrow-therapeutic-index drugs should seek medical advice before adding herbal products. New fatigue, bleeding, jaundice, rash, fainting, severe gastrointestinal symptoms, or other suspected adverse effects require prompt clinical evaluation rather than dosha-based self-correction.

The Road Ahead: What Research Is Needed

Ayurgenomics could become more informative if future studies move from retrospective molecular association to prospective clinical testing. The essential question is not merely whether groups differ, but whether Prakriti adds accurate, reproducible, and clinically useful prediction after known genetic and clinical variables are included.

• Pre-registered, adequately powered studies using clearly specified and independently validated Prakriti instruments
• Direct pharmacokinetic testing with defined probe drugs, measured concentrations, and prespecified outcomes
• Replication in women and men across ages, ancestries, regions, body compositions, and disease populations
• Parallel measurement of relevant genotypes, liver and kidney function, diet, co-medication, adherence, and environmental factors
• Separation of innate Prakriti from current vikriti and temporary disease-related phenotypes
• External validation showing that Prakriti improves prediction beyond ordinary clinical assessment and established pharmacogenomics
• Prospective evaluation of adverse drug reactions, therapeutic response, and cost-effectiveness before clinical implementation

Until those requirements are met, Ayurgenomics is best understood as a promising phenotype-to-biology research program, not a bedside dosing system. Its value may lie in generating hypotheses and refining cohorts for investigation, but clinical utility must be demonstrated rather than assumed.

A Note on Traditional Ayurveda

Classical Ayurveda does emphasize individualized examination. In Charaka Samhita, Prakriti is one relevant feature of the patient, not the sole basis of treatment. The physician is expected to assess the person, the disorder, strength, current imbalance, suitability, diet, environment, and the properties of the proposed intervention. The Prakriti passages are in Vimana Sthana 8/95–99, not Sharira Sthana Chapter 4.

This individualized orientation is conceptually compatible with the goal of precision medicine, but conceptual similarity is not scientific equivalence. Pharmacogenomics links particular variants to particular drugs under defined conditions; Prakriti is a multidimensional clinical construct. Respecting both traditions requires keeping those categories distinct until direct evidence justifies a bridge.

Educational content cannot replace personal medical care. Consult a qualified physician before changing any medicine and a qualified Ayurvedic practitioner for individualized Ayurvedic assessment. Seek urgent care for serious or rapidly worsening symptoms.

References

1. Link (link.springer.com)
2. Charaka Samhita — Prakriti
3. Charaka Samhita — Rogabhishagjitiya Vimana
4. Nature (nature.com)
5. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
6. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed Central
7. Pubs (pubs.acs.org)
8. Pnas (pnas.org)
9. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed
10. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed Central
11. Frontiersin (frontiersin.org)
12. Cpicpgx (cpicpgx.org)
13. Cpicpgx (cpicpgx.org)
14. Cpicpgx (cpicpgx.org)